SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

…, ML Pachowsky, F Schuch, M Ronneberger… - Annals of the …, 2021 - ard.bmj.com
Objectives To better understand the factors that influence the humoral immune response to
vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (…

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised …

…, J Wendler, F Schuch, M Ronneberger… - Annals of the …, 2016 - ard.bmj.com
Objective To prospectively analyse the risk for disease relapses in patients with rheumatoid
arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-…

[HTML][HTML] Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

…, M Pachowsky, F Schuch, M Ronneberger… - Nature …, 2020 - nature.com
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with
inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of …

Pathophysiology of spondyloarthritis

M Ronneberger, G Schett - Current rheumatology reports, 2011 - Springer
Spondyloarthritis (SpA) is characterized by inflammation and new bone formation in the spine
and entheses. The disease is the result of a complex interplay among susceptibility genes, …

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment

…, M Ronneberger, M Feuchtenberger, M Fleck… - Annals of the …, 2016 - ard.bmj.com
Objective To analyse the role of multibiomarker disease activity (MBDA) score in predicting
disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who …

Humoral and cellular immune responses to SARS–CoV‐2 infection and vaccination in autoimmune disease patients with B cell depletion

…, K Manger, F Schuch, M Ronneberger… - Arthritis & …, 2022 - Wiley Online Library
Objective B cell depletion is an established therapeutic principle in a wide range of
autoimmune diseases. However, B cells are also critical for inducing protective immunity after …

Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic …

…, M Ronneberger, M Feuchtenberger, M Fleck… - Annals of the …, 2017 - ard.bmj.com
Objective To perform a detailed analysis of the autoantibody response against post-translationally
modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and …

Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial

…, S Kleinert, J Wendler, M Ronneberger… - The Lancet …, 2021 - thelancet.com
Background Owing to increasing remission rates, the management of patients with rheumatoid
arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing …

[HTML][HTML] Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS–CoV‐2 in an …

…, F Schuch, M Ronneberger… - Arthritis & …, 2022 - Wiley Online Library
Objective To investigate the impact of biologic disease‐modifying antirheumatic drug (bDMARD)
treatment on the prevalence, seroconversion rate, and longevity of the humoral immune …

Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade

J Rech, M Ronneberger, M Englbrecht… - Annals of the …, 2011 - ard.bmj.com
Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology.
1 Based on the substantial acute phase responses observed in AOSD, we hypothesised …